Clinical Experience With Levosimendan in the Emergency Department of a Tertiary Care Hospital

Llorens‐Soriano, Pere; Carbajosa-Dalmau, José; Fernández‐Cañadas, José María; Murcia-Zaragoza, José; Climent-Payá, Vicente E.; Laghzaoui, Fadoua; Diéguez-Zaragoza, Santiago; Carrasco-Moreno, Rafael

doi:10.1016/s1885-5857(08)60033-x

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levosimendan is reported to be effective in adults with cardiac failure after subarachnoid hemorrhage. [17][18][19] Our study patients recovered from myocardial stunning; however, both died due to their neurological complications. In the second patient, an infectious etiology was suspected, with fatal refractory brain edema; however, the causative organism was not detected.…”

Section: Discussionmentioning

confidence: 77%

Neurogenic Stunned Myocardium in Two Children with Neurological Injury

Ruiz

Lorenzo

Sáez

2019

J Pediatr Intensive Care

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 77%

Neurogenic Stunned Myocardium in Two Children with Neurological Injury

Ruiz

Lorenzo

Sáez

2019

J Pediatr Intensive Care

View full text Add to dashboard Cite

show abstract

“…Additionally, in chronic HF patients, levosimendan may be the only remaining pharmacological option. This notion is strengthened by the results of a small prospective descriptive study levosimendan showed to be effective and safe in patients with AHF in the ED [9].…”

Section: Levosimendan In the Early Phase Of The Treatment Of Ahfmentioning

confidence: 99%

Levosimendan: a decade of experience in Europe built on years of evidence

Parissis¹,

Toller²,

Franco³

et al. 2008

European Journal of Heart Failure Supplements

View full text Add to dashboard Cite

Recent European Society of Cardiology's (ESC) guidelines on the diagnosis and treatment of acute heart failure (AHF), suggest that an essential target in the management of these patients is to improve symptoms within hours, which should persist until hospital release, also protecting renal function and avoiding ongoing myocardial injury. The vast experience built on the basis of evidence, accumulated regarding the use of levosimendan over the last 10 years, brings with it the possibility of utilizing this drug in multitude of new clinical scenarios. Newly discovered biologic effects of the drug on the failing heart, based on its anti‐inflammatory, anti‐apoptotic and anti‐oxidative properties may explain the clinical efficacy of levosimendan in special sub‐populations of AHF patients. This paper summarizes the current knowledge regarding the use of levosimendan in the early phase of the treatment of AHF, in acute coronary syndromes, its daily use in the critical care environment, perioperatively, and in patients with renal failure.

show abstract

“…Despite a decade of research, levosimendan's role in the management of acute heart failure is still unclear. Multiple small studies have demonstrated improvements in haemodynamic and renal function in acute heart failure, 34,48,103–105 including use in the ED 106 . Initial outcome‐based trials comparing levosimendan with dobutamine 102,107 in decompensated cardiac failure showed promise in both cardiovascular and renal outcomes and survival, with the mortality benefit sustained for up to 6 months.…”

Section: Inotrope Choice In Specific Shock Statesmentioning

confidence: 99%

Review article: Inotrope and vasopressor use in the emergency department

Senz¹,

Nunnink²

2009

Emerg Medicine Australasia

View full text Add to dashboard Cite

Shock is a common presentation to the ED, with the incidence of septic shock increasing in Australasia over the last decade. The choice of inotropic agent is likely dependent on previous experience and local practices of the emergency and other critical care departments. The relatively short duration of stay in the ED before transfer leaves little room for evaluating the appropriateness of and response to the agent chosen. Delays in transfer to inpatient facilities means that patients receive advanced critical care within the ED for longer, requiring initiation and titration of vasoactive agents in the ED. This article discusses the general concepts of shock and the indicators for inotrope and vasopressor use, revises the various agents available and reviews the current evidence for their use.

show abstract

Clinical Experience With Levosimendan in the Emergency Department of a Tertiary Care Hospital

Cited by 3 publications

References 16 publications

Neurogenic Stunned Myocardium in Two Children with Neurological Injury

Neurogenic Stunned Myocardium in Two Children with Neurological Injury

Levosimendan: a decade of experience in Europe built on years of evidence

Review article: Inotrope and vasopressor use in the emergency department

Contact Info

Product

Resources

About